Inhibrx’s OX40 data provide a rationale—not yet proof—for a cancer-vaccine combination on September 08, 2026 Anti-OX40 Hexavalent Agonist Antibody INBRX-106 HPV-positive cancer Inhibrx Biosciences Keytruda OX40 agonist pembrolizumab Phase 2 Squamous cell carcinoma of the head and neck therapeutic cancer Vaccines +